Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture
Sleep Medicine · 2024
DOI: 10.1016/j.sleep.2023.12.015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Sleep Medicine, 2024. Verfasst von Thomas Roth und 4 weiteren Autor:innen. Beteiligte Einrichtung: Henry Ford Hospital, Detroit, MI, USA. Electronic address: troth1@hfhs.org. Hauptthemen laut MEDLINE: Sodium Oxybate, Narcolepsy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jazz Pharmaceuticals.
Abstract (Originalsprache)
Many components of sleep are disrupted in patients with narcolepsy, including sleep quality, sleep architecture, and sleep stability (ie, frequent awakenings/arousals and frequent shifts from deeper to lighter stages of sleep). Sodium oxybate, dosed twice nightly, has historically been used to improve sleep, and subsequent daytime symptoms, in patients with narcolepsy. Recently, new formulations have been developed to address the high sodium content and twice-nightly dosing regimen of sodium oxybate: low-sodium oxybate and once-nightly sodium oxybate. To date, no head-to-head trials have been conducted to compare the effects of each oxybate product. This review aims to give an overview of the existing scientific literature regarding the impact of oxybate dose and regimen on sleep architecture and disrupted nighttime sleep in patients with narcolepsy. Evidence from 5 key clinical trials, as well as supporting evidence from additional studies, suggests that sodium oxybate, dosed once- and twice-nightly, is effective in improving sleep, measures of sleep architecture, and disrupted nighttime sleep in patients with narcolepsy. Direct comparison of available efficacy and safety data between oxybate products is complicated by differences in trial designs, outcomes assessed, and statistical analyses; future head-to-head trials are needed to better understand the advantage and disadvantages of each agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henry Ford Hospital, Detroit, MI, USA. Electronic address: troth1@hfhs.org.
- Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France; University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France.
- Medical University of South Carolina, Charleston, SC, USA; Bogan Sleep Consultants, LLC, Columbia, SC, USA.
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio-Emilia, Modena, Italy; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
- Stanford University Center for Sleep Sciences and Medicine, Palo Alto, CA, USA; Jazz Pharmaceuticals, Palo Alto, CA, USA.
Förderung
- Jazz Pharmaceuticals
Zitieren
APA
Roth, T., Dauvilliers, Y., Bogan, R. K., Plazzi, G., & Black, J. (2024). Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture. Sleep Medicine. https://doi.org/10.1016/j.sleep.2023.12.015
Vancouver
Roth T, Dauvilliers Y, Bogan RK, Plazzi G, Black J. Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture. Sleep Medicine. 2024. doi:10.1016/j.sleep.2023.12.015
BibTeX
@article{Roth2024,
author = {Roth, Thomas and Dauvilliers, Yves and Bogan, Richard K and Plazzi, Giuseppe and Black, Jed},
title = {Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture},
journal = {Sleep Medicine},
year = {2024},
doi = {10.1016/j.sleep.2023.12.015}
}
EUVIMED